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IMPROVING MICHIGAN'S GENERIC DRUG LAW
During 1974 consumer advocates' and the Michigan Pharmaceutical As-
sociation, 2 convinced the Michigan Legislature to enact a law3 designed to
bring down the price of drugs for consumers. This legislation is popularly
known as the drug substitution 4 or generic drug 5 law.
Those who supported enactment of the generic drug law identified lack
of competition as a major cause of high prescription drug prices. 6 They
reasoned that this situation was fostered by the common medical practice
of prescribing drugs by brand name rather than by generic name.7 A
"generic" name is a non-proprietary name used to designate drug products
with the same active ingredients in the same dosage form.8 It is also referred
to as the usual, established, or official name. 9 A "brand" or "trade" name
is a designation given to a drug by a manufacturer, which, if registered, can
be used exclusively by that firm. A brand name is not required in order to
market a drug but is often used to distinguish one company's drug product
from other products in the same generic category. 10
Prior to passage of the generic drug law, a pharmacist filling a prescrip-
tion written by brand name was required to dispense only that brand-name
product to the customer," regardless of the availability of lower cost
chemical equivalents marketed under other brand names or simply under
the generic name of the drug. The Michigan generic drug law, under cer-
tain circumstances, now permits a pharmacist to dispense a chemically
1 The Michigan Citizens Lobby, a Detroit-based consumer group, was a major
force in passage of the new law. Detroit Free Press, July 6, 1975, at 3A, col. 1.
2 H.B. 4145 Analysis, 12 MICH. PHARM. 7, 7-8 (April 1974). The Michigan Pharma-
ceutical Association represents 3,000 state pharmacists. Ann Arbor News, Jan. 4,
1976, at 7, col. 1.
3 No. 155, [1974] Mich. Pub. Acts (effective April 1, 1975), amending MICH. COMP.
LAWS ANN. §§ 338.1101, 338.1115, 338.1123, 338.1128 (Supp. 1975-76) and adding
MICH. COMp. LAWs ANN. §§ 338.1114a-d, 338.1124a (Supp. 1975-76).
4 MICH. ATTY GEN. Op. No. 4839 (Feb. 5, 1975).
5 See Ann Arbor News, Sept. 11, 1975, at 23, col. 1.
6 Statement of State Reps. Joseph Forbes & H. Lynn Jondahl, Hearing on H.B.
4145 Before the Senate Agricultural and Consumer Aflairs Comm., 77th Leg. (April
23, 1974).
7 See note 16 infra.
8 Note, Products Liability for Prescription Drugs-The Effects of Generic Sub-
stitution on the Consumer and the Pharmacist, 23 SYR. L. REV. 887, 887 (1972).
9 Willig, The Prosubstitution Trend in Modern Pharmacy Law, 6 U. MICH. J.L.
REFORM 1, 8 (1972).
10 Note, supra note 8, at 888.
11 See notes 23, 24 and accompanying text infra.
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equivalent drug in place of a prescribed brand-name product. In other
words, the law authorizes "generic substitution.'
12
This note will describe the conditions which existed prior to enactment
of the Michigan drug substitution law, will discuss the history and pro-
visions of that legislation, and will identify certain problems which the law
fails to correct.
I. THE PRICE DIFFERENTIAL PROBLEM
The price differences between brand-name and generic-name drug
products can be substantial."3 An Oklahoma study which compared the
prices paid by pharmacists for brand-name versions and their generic-name
equivalents of eight major drugs showed that, in general, the brand-name
prices were more than three times the prices for the generic-name prod-
ucts. 1 4 It is questionable whether such marked variations in price accurately
reflect any differences in quality. A drug product is frequently manufac-
tured by one pharmaceutical company and then sold to other firms which
market it under their own brand names. Price differences among these
12 Other states have instituted similar reforms. For example, see ARK. STAT. ANN.
§§ 72-1047 to -1049 (Supp. 1975) (A pharmacist may dispense a lower cost generic
equivalent unless it appears on a Non-Equivalent Drug Product List promulgated by
the State Health Officer. A prescriber or the patient may demand that the prescrip-
tion be dispensed as communicated.); CAL. Bus. & PROF. CODE §§ 4047.6-.7 (Ch. 1144
[1975] 7 Deering Advance Leg. Service 442) (Substitution of a lower cost drug
product which does not appear on a state formulary is permitted unless the doctor
has written "Do not substitute." See notes 116-19 and accompanying text infra.);
FLA. STAT. ANN. § 465.30 (Supp. 1975) (Every prescription must bear the phrases
"Substitution Allowed" and "Prior Approval Required," one of which must be
initialed by the prescriber. Only a less expensive equivalent may be dispensed.); KY.
REV. STAT. ANN. §§ 217.818-19, 217.822 (Supp. 1974) (Pharmacist may substitute
from a state formulary and must do so if the purchaser requests, unless the pre-
scriber has written "Do not substitute." See notes 112-15 and accompanying text
in/ra.); ME. REV. STAT. ANN. tit. 32, § 2806 (Supp. 1975-76) (A pharmacist may
substitute an equivalent drug listed in the National Formulary or United
States Pharmacopeia unless the doctor has indicated otherwise. The price of the
dispensed drug may not exceed the price of the prescribed drug.); MD. ANN. CODE
art. 43, § 273A (Cum. Supp. 1975) (A pharmacist may substitute an equivalent
product pursuant to a state formulary or federal regulations unless the prescriber
has indicated otherwise. See note 115 infra. The savings in cost must be passed on
to the consumer.); MASS. GEN. LAWS ANN. ch. 112, § 12D (1975) (A physician who
prescribes a drug listed on the state formulary is required to include the generic
name of such drug.); MINN. STAT. ANN. § 151.21 (Ch. 101 [1975] Minn. Session
Law Service 295) (A pharmacist may substitute with the purchaser's consent unless
the prescriber has indicated the prescription is to be dispensed as written. The
substituted drug must not bear a higher retail price than the product prescribed, and
any savings must be passed on to the purchaser. See notes 88, 102-03 and accom-
panying text infra.); Ch. 218, §§ 3-4 [1975] Ore. Laws 287 (Unless the purchaser
instructs otherwise, or unless the prescriber prohibits substitution, a pharmacist may
substitute a generic equivalent, which is in his professional opinion therapeutically
equivalent. The substitution must result in a savings or no increase in cost to the
purchaser.)
13 See M. SILVERMAN & P. LEE, PILLS, PROFITS, AND POLITIcs 334 (1974) for ex-
amples of price ratios ranging from 5.7:1 to 35.9:1 [hereinafter cited as M. SILVER-
MAN].
14 Green, Welfare Losses from Monopoly in the Drug Industry: The Oklahoma
'Antisubstitution Law,' 5 ANTITRUST LAW & ECON. REV. 97, 100 (Spring 1972).
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brands have also been found to vary by over 300 percent, in spite of the
fact that they come from the same source.15
Most prescriptions are written by brand name. 16 This is partly attrib-
utable to the fact that trade names are generally shorter and easier to spell
than their corresponding generic designations.' 7 Brand-name prescribing
also can be attributed to the fact that a new drug formula can be patented.
Throughout the seventeen years when its manufacturer has a monopoly on
its production, the drug is usually marketed exclusively under a brand
name.' 8 During this period, the brand name becomes so closely associated
with the drug in the minds of physicians that they continue to write it when
prescribing the drug long after the patent has expired. 19 The association of
drug formulas with brand names is fostered by major pharmaceutical firms
which carry on extensive advertising programs. 20 The core of these promo-
tional campaigns is the company detail man, 21 who makes personal visits
to physicians in order to inform them of newly available drugs and to pro-
mote the represented company's products.
22
15 The following examples were cited by Richard P. Penna, Pharm. D., in testi-
mony before the Michigan Senate Agriculture & Consumer Affairs hearing on H.B.




Manufacturer Distributor (per 100)
Chloral R. P. Scherer Squibb $5.00
Hydrate (500 Lemmon Pharmacal 2.90
Milligram Stanlabs 2.15
Capsules) Alliance Labs 1.75
McKesson 1.75
Pure Pac 1.48
Tetracycline Milan A.H. Robins 3.25
HCL (250 Smith, Kline & French 3.40
Milligram Wyeth 2.06
Capsules) Towne Paulsen 1.50
Alliance Labs 2.50
Central Pharmacal 2.50
.16 The 15th Annual Prescription Survey of the Albany College of Pharmacy (1971)
indicated that almost 90 percent of all prescriptions were written by brand name.
Note, supra note 8, at 888. In a recent Michigan survey, doctors were asked how often
they write prescriptions generically. Thirty-eight percent stated they "sometimes"
prescribe generically; another 23 percent claimed that they prescribe generically
"whenever possible." T. GOLDBERG. W. MOORE, et al., PRELIMINARY REPORT OF
SURVEY OF ATTITUDES AND INTENDED BEHAVIOR OF PHYSICIANS AND PHARMACISTS,
at 19, Nov. 16, 1975 (Dept. of Community Medicine, Wayne State U.) [hereinafter
cited as T. GOLDBERG]. The executive director of the Michigan Pharmaceutical As-
sociation estimates that about 10 to 15 percent of all prescriptions are written gener-
ically. See Sesti, Testimony on H.B. 5325, 13 MICH. PHARM. 6 (Aug. 1975).
17 See M. SILVERMAN, supra note 13, at 323-26. For example, Declomycin is a
brand name for the generic drug demethylchlortetracycline. Id. at 324.
18 Green, supra note 14, at 102.
19 Id; M. SILVERMAN, supra note 13, at 36.
20 M. SILVERMAN, supra note 13, at 36, 54-57.
21 TASK FORCE ON PRESCRIPTION DRUGS, THE DEPARTMENT OF HEALTH, EDUCA-
TION, AND WELFARE, THE DRUG PRESCRIBERS 14 (1968).
22 Id. at 14-15.
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Before the current generic drug law was passed, if the detail man could
"educate" a doctor to prescribe his firm's product by its trade name, a
Michigan pharmacist filling the prescription was restricted to dispensing
only that brand, even if lower cost equivalents were available. To "substi-
tute any drug or device knowing or intending that it shall be used" was a
misdemeanor. 23 The word "substitute" was defined as "to dispense without
prescriber's authorization a different drug or brand of drug in place of the
drug or brand of drug ordered or prescribed. ' 24 A pharmacist could dis-
pense a different brand of product by telephoning the prescriber for his
permission, but this was not always possible or convenient.
The former antisubstitution law thus created a twofold problem. First,
the consumer with a prescription for a drug product obtainable from dif-
ferent sources was prevented from exercising any choice among diversely
priced equivalents if his prescription was written by trade name. The irony
of this situation was that in many cases the prescribing doctor had no real
preference as to brand but was simply writing the name which was most
familiar to him, without considering the factor of cost.25 Second, companies
which succeeded in familiarizing doctors with their brand-name products
were able to escape the competitive pressures of a normal market because
the individuals choosing the drug products were not the ones paying the
bills.2 6 As a result, certain drug suppliers were able to charge prices that
were much higher than prices charged by their "competitors." The element
of competition was lacking in one additional respect. In shopping for over-
the-counter drug items the consumer could easily compare the prices
charged by various retailers in his vicinity by simply referring to their price
tags. To ascertain the price being charged for a prescription drug, however,
it was necessary to ask the pharmacist.
II. HISTORY OF THE ACT
The ban on substituting a different brand of drug in place of the brand
prescribed 2T aroused the opposition of consumers and pharmacists alike.
However, these groups proposed different solutions to the antisubstitution
problem.
The Michigan Pharmaceutical Association (MPA) advocated outright
repeal of the antisubstitution law. The pharmacists therefore asked Mich-
igan Representative Joseph Forbes to introduce a bill which would change
the definition of "substitute" by striking out all reference to "brand of
drug."'28 It was expected that a simple repeal of the prohibition against
23 MICH. COMP. LAWS ANN. § 338.1117(1) (1967).
2 4 MICH COMP. LAWS ANN. § 338.1101(u) (1967) (emphasis added), as amended,
(Supp. 1975-76).
25 The information provided by detail men rarely includes price of the product.
TASK FORCE ON PRESCRIPTION DRUGS, DEPARTMENT OF HEALTH, EDUCATION, AND
WELFARE, FINAL REPORT 10 (1969).
26 Green, supra note 14.
27 See notes 23, 24 and accompanying text supra.
28 H.B. 4145 Analysis, supra note 2, at 7. MICH. COMP. LAWS ANN. § 338.1101(u)
would thus read: "Substitute means to dispense, without the prescriber's authoriza-
tion, a different drug in place of the dug prescribed."
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brand interchange would maximize the scope of pharmacists' professional
responsibility in selecting which drug products to dispense. 29 House Bill
4145, which embodied the MPA's recommendation, was introduced by
Representative Forbes on February 14, 1973.30
Consumer advocates, on the other hand, formulated a bill31 which com-
bined a concern for insuring efficacious drug therapy with the goal of cut-
ting pharmaceutical costs. This bill was introduced by Representative
Forbes and Representative H. Lynn Jondahl as House Bill 4593 on April
30, 1973.32 The consumer version would have created a nine-member drug
equivalency commission' 3 charged with preparing a formulary of drugs and
pharmaceuticals. 34 The formulary would list brand-name drugs and generic
counterparts which the commission had determined were therapeutically
equivalent.' 5 A pharmacist who received a prescription for a brand-name
drug listed on the formulary would be permitted to dispense an equivalent
drug from the list and would be required to do so upon the purchaser's
request.' 6 A doctor could write "Do Not Substitute" on a prescription if
he felt an equivalent drug should not be dispensed.' 7 Any savings resulting
from the substitution were to be passed on to the consumer.' 8 Another
provision of House Bill 4593 called for pharmacists to post conspicuously
their current retail prices for the one hundred most frequently prescribed
drugs.' 9 The Department of Health was to gather and record these posted
prices, publish a list of drugs and their retail prices, and distribute copies
of the list to interested parties.
40
House Bills 4145 and 4593 were both referred to the House Committee
on Consumers and Agriculture, 4' where an effort was made to synthesize
them into a bill which could be supported by consumers and pharmacists.
The MPA opposed both the consumers' proposal that prices be posted for
the most frequently prescribed drugs and the restriction of professional
responsibility which the formulary concept entailed. 42 Eventually a com-
promise was reached, 42 and it was agreed to retain the price posting require-
29 See H.B. 4145 Analysis, supra note 2.
30 H.B. 4145, 77th Leg. (1973).
31 See H.B. 4145 Analysis, supra note 2, at 7.
32 H.B. 4593, 77th Leg. (1973).
33Id. § 2(1).
34 Id. § 4.
35 Id. The bill was strikingly similar to KY. REV. STAT. ANN. §§ 217.818-19,
217.822 (Supp. 1974).
6 H.B. 4593, 77th Leg., § 5(1) (1973).
37 Id. at § 5(2).
38 Id. at § 5(3).
39 Id. at § 9(1). The Department of Health was to determine which drugs were to
be included on this list. Id.
40 Id. § 11.
41 MICH. H.R. JOUR. No. 12, at 316 (Feb. 14, 1973); MICH. H.R. JOUR. No. 43, at
925 (April 30, 1973).
42 See H.B. 4145 Analysis, supra note 2, at 7, 22.
43 Id. at 8, 22.
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ment of House Bill 4593 but drop its formulary provisions. 4 4
This compromise solution was drawn up as a substitute bill45 and re-
ported out of committee on February 7, 1974.46 One section of the bill
redefined the word "substitute" as urged by the pharmacists. 47 Another
section embodied the consumers' proposals regarding generic substitution,
except for the provision for a drug formulary. 4s The bill was extensively
debated in both the House and Senate, where numerous amendments were
proposed and over a dozen adopted. 49 These amendments render the law
as finally passed susceptible to contradictory interpretations. 50
III. PROVISIONS OF THE CURRENT
GENERIC DRUG ACT
A. Circumstances Under Which Generic
Substitution Is Permitted
The core of the generic drug law is section 14a, 51 which provides that a
pharmacist may dispense a generically equivalent drug product in place of
the brand prescribed if the substituted product is lower in cost.52 The sec-
tion further commands that the resulting savings be passed on to the con-
sumer.53 Both the name of the prescribed drug and the brand or generic
name of the dispensed drug must appear on the prescription label when-
ever substitution occurs.54 Section 14a provides several methods, however,
by which prescribers can prevent generic substitution altogether.55 The law
also permits a pharmacist to dispense a product which is higher in cost than
the brand prescribed if the purchaser consents. 56
44 The House Committee on Consumers and Agriculture
evaluated the experience with 'formularies' in Massachusetts and Ken-
tucky and observed a multitude of problems in their operations. In
addition, the estimated costs of creating a State Drug Equivalency Com-
mission were substantial enough to raise the question of whether the
product would be equivalent to the investment.
Letter from H. Lynn Jondahl to author, Oct. 27, 1975 (on file with the University
of Michigan Journal of Law Reform).
45 Substitute H.B. 4145, 77th Leg. (1973).
46 MICH. H.R. JouR. No. 15, at 287 (Feb. 7, 1974).
47 Substitute H.B. 4145, 77th Leg., § 1(u) (1973). See note 28 and accompanying
text supra.
48 Substitute H.B. 4145, 77th Leg., § 14a (1973).
49 See MICH. H.R. JOUR. No. 20, at 385-94 (Feb. 14, 1974); MICH. H.R. JOUR.
No. 22, at 445-47 (Feb. 20, 1974); MICH. H.R. JOUR. No. 23, at 471-79 (Feb. 21,
1974); MICH. H.R. JOUR. No. 26, at 521-28 (Feb. 26, 1974); MICH. S. JOUR. No. 69,
at 982 (May 20, 1974); MICH. S. JOUR. No. 74, at 1047-50 (May 29, 1974).
50 See part III A 1 infra.
51 MICH. COMP. LAWS ANN. § 338.1114a (Supp. 1975-76).
52 
MICH. COMp. LAWS ANN. § 338.1114a(1) (Supp. 1975-76).
53 MICH. COMP. LAWS ANN. § 338.1114a(2) (Supp. 1975-76).
54 MICH. COMP. LAWS ANN. § 338.1114a(1) (Supp. 1975-76).
5 5
MIcH. COMP. LAWS ANN. § 338.1114a(3) (Supp. 1975-76). See part III A 3
infra.
5 6
MICH. COMP. LAWS ANN. § 338.1114a(4) (Supp. 1975-76).
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1. Is a Purchaser Request a Prerequisite for Generic Substitution?-
Even before the generic drug law took effect, language in section 14a(1)
generated conflicting interpretations. The major controversy is whether the
phrase "and the purchaser requests a lower cost generically equivalent drug
product"5 7 implies that the customer must first request generic substitution
before the pharmacist can dispense a different brand of drug than the brand
prescribed.
The Michigan Pharmaceutical Association has taken the position that a
prior request is not necessary.5 8 According to the MPA, the Act's redefini-
tion of the word "substitute" 59 makes it "entirely the prerogative of the
pharmacist to perform drug product selection." 60 The MPA views section
14a(1) simply as mandating that, if a customer does request a lower cost
equivalent, the substitution must result in a savings to him unless he agrees
to the contrary. 61 An additional purpose of the section, as interpreted by
the MPA, is to prohibit substitution where the prescriber has indicated that
the prescription is to be dispensed as written.
6 2
The MPA contends that it was not the intent of the bill's sponsors to
make a request by the purchaser a prerequisite of substitution,63 and the
legislative history of the generic drug act lends support to this position.
When reported out of committee, Substitute House Bill 4145 originally
read:
When a pharamacist receives a prescription for a brand
name drug product, and the purchaser requests a lower cost
drug product, the pharmacist shall dispense a lower cost
drug product if available in the pharmacy .... 64
In drafting the compromise bill, the committee had attempted to combine
the desire of pharmacists for more professional responsibility with the de-
sire of consumer advocates to save money. The pharmacists were
accommodated by removing words which prohibited brand interchange
from the definition of "substitute." The consumers, on the other hand, were
given the right to demand substitution of lower cost generically equivalent
drugs, if available in the pharmacy. Therefore, as originally written, the
"purchaser request" clause merely compelled the pharmacist to substitute
generic equivalents upon consumer demand. Although the bill did not ex-
plicitly state that the pharmacist was free to substitute when the purchaser
57 MICH. COMP. LAWS ANN. § 338.1114a(l) (Supp. 1975-76) reads in pertinent part
as follows:
When a pharmacist receives a prescription for a brand name drug
product, and the purchaser requests a lower cost generically equiv-
alent drug product, the pharmacist may dispense a lower cost but
not higher cost generically equivalent drug product if available in the
pharmacy ....
58 Understanding H.B. 4145, 12 MICH. PHARM. 7, 7-8 (Aug. 1974).
5aMIcH. COMp. LAws ANN. § 338.1101(u) (Supp. 1975-76), amending MICH.
CoMP. LAws ANN. § 338.1101(u) (1967). See note 47 and accompanying text supra.
60 Understanding H.B. 4145, supra note 58, at 8.
61 Id.
62 Id.
63 MICHIGAN PHARMACY BULLETIN, Mar. 28, 1975.
64 Substitute H.B. 4145, 77th Leg., § 14a(1) (1973) (emphasis added).
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expressed no preference on this matter, the removal of the language which
had prohibited brand interchange implied such authority.
During debate, however, the House of Representatives passed an amend-
ment which removed the obligation of the pharmacist to honor a
customer's request for a lower cost substitute. The amendment replaced
the verb "shall" in the first sentence of section 14a(1) with the word
"may. '65 As a result, the clause which had been intended to specify when a
pharmacist is compelled to substitute now seemed designed to specify when
a pharmacist is permitted to substitute. Nevertheless, it is possible that the
amendment was not intended to restrict the pharmacist's authority to sub-
stitute. It may have been directed at allowing the pharmacist to refuse to
substitute in situations where he did not feel a generic equivalent would
provide the same therapeutic effect as the prescribed brand-name drug.66
A subsequent attempt to amend the bill in the House also supports the
conclusion that a purchaser request is not required before a pharmacist
can substitute a generic equivalent. This amendment, which would have
stipulated that a generically equivalent drug product could not be dispensed
unless agreed to by the purchaser,
67 failed to pass. 68
One month after the Michigan Pharmaceutical Association explained its
understanding of the new law in its state professional journal,6 9 the Board
of Pharmacy requested an opinion of the Michigan Attorney General 70 on
the question "whether a pharmacist may dispense a generically equivalent
drug product in the absence of a request by the purchaser. '71 The Attorney
General ruled that, with one exception, the answer to this question 'was
negative.72
The Opinion of the Attorney General briefly mentions the deletion of
any reference to the phrase "or brand of drug" in the definition of "substi-
tute,"' 73 stating that this change now permits a pharmacist to dispense a
generic equivalent in place of a prescribed brand without first obtaining the
prescriber's authorization. The Opinion continues that, "having narrowed
the definition of substitution," the legislature set forth "simply and suc-
cinctly" the circumstances under which generic substitution could take
place.74 Four conditions must first be met, one of which is a request from
the purchaser.
75
65 MICH. H.R. JOUR. No. 22, at 446 (Feb. 20, 1974).
66 See part IV A infra.
67 MICH. H.R. JOUR. No. 23, at 477 (Feb. 21, 1974).
68 Although the amendment failed, it was supported by 54 of the 110 members of
the House of Representatives serving. Id. The sponsor of the amendment succeeded
in getting the House to reconsider it (id. at 478), but subsequently withdrew it.
MICH. H.R. JOUR. No. 26, at 521 (Feb. 26, 1974).
69 Understanding H.B. 4145, supra note 58.
70 Sesti, Representing Pharmacy Everyday in the Michigan Legislature, 13 MICH.
PHARM. 16 (Aug. 1975).
71 MICH. ATr'Y GEN. Op. No. 4839 (Feb. 5, 1975).
72 Id.
73MICH. COMP. LAWS ANN. § 338.1101(u) (Supp. 1975-76), amending MICH.
COMP. LAws ANN. § 338.1101(u) (1967).
74 MICH. ATr'Y GEN. Op. No. 4839, at 2, 4 (Feb. 5, 1975).
75The four conditions are: (1) a prescription written by brand name; (2) a re-
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An important exception to the purchaser request requirement was iden-
tified, however. If, pursuant to section 14a(3)(b), the prescriber used a pre-
printed prescription blank bearing the statement, "another brand of a
generically equivalent product, identical in dosage, form, and content of
active ingredients, may be dispensed unless initialed D.A.W.," 7 then a
purchaser request would not be a prerequisite to generic substitution. 77 The
Opinion reasoned that such a statement itself serves as authorization by the
prescriber for the pharmacist to dispense a generic equivalent. In other
words, the prescription is essentially written by generic name. According to
the Opinion, not only would a patient request then be unnecessary, but the
language of section 14a(1), requiring that the drug dispensed have a lower
cost than the product prescribed, would also be inapplicable. However,
section 1 4a(4) would still limit the total cost for the drug dispensed to the
cost of the drug prescribed.
78
An argument in support of the interpretation that a purchaser request is
a prerequisite for substitution might be made based upon language in sub-
section 14a(3), 79 which preserves the physician's power to prevent substi-
tution. This section states:
The pharmacist shall not dispense a generically equivalent
drug product under subsection (1) of this section if ... [the
prescriber indicates the prescription is to be dispensed as
written],80
This section only refers to substitution performed "under subsection
[14a](1)," which grants the pharmacist authority to dispense an equivalent
drug product in response to a request from the customer.8 1 Thus, subsection
14a(3) is silent as to substitution initiated by the pharmacist rather than by
the customer. Since it is highly unlikely that the legislature intended to give
doctors the power to veto generic substitution when initiated by the patient
quest from the purchaser that a lower cost generically equivalent drug be dispensed;
(3) an equivalent product having an actual cost lower than that of the prescribed
product, unless the purchaser agrees otherwise; (4) no indication that the prescription
be dispensed as written. Id. at 4, 5.
76 MICH. COMP. LAWS ANN. § 338.1114a(3)(b) (Supp. 1975-76). The initials
"D.A.W." signify that a prescription is to be "dispensed as written." See part III
A 3 infra.
77 MICH. A-r'Y GEN. Op. No. 4839, at 5 (Feb. 5, 1975).
78 It is difficult to understand why the Attorney General attributed such an effect
to the inclusion of these words on a prescription blank. The phrase, "another brand
of a generically equivalent product, identical in dosage, form, and content of active
ingredients, may be dispensed unless initialed D.A.W.," merely reports what the law
is. A prescription blank bearing such a statement therefore should not be con-
sidered any more of an authorization for generic substitution than a prescription
blank which does not carry this restatement of the law. The ruling that the require-
ment for a purchaser request depends upon the type of prescription blank used
by the prescriber is arbitrary. Although the words of the Act can be construed
in this way, no purpose is served by linking the purchaser request requirement to
the prescriber's prescription form.
79 MICH. COMP. LAWS ANN. § 338.1114a(3) (Supp. 1975-76).
sold. (emphasis added). This language was added by amendment. MICH. S. JOUR.
No. 74, at 1047-48 (May 29, 1974).
81 MICH. COMP. LAWS ANN. § 338.1114a(l) (Supp. 1975-76).
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but not when initiated by the pharmacist, the legislature must have con-
sidered generic substitution to be permissible only pursuant to subsection
14a(1). This undermines the position that "[t]he authority for the pharma-
cist to perform drug product selection ... is inherent in the re-definition of
the word 'substitute' .".8.2
In stating that the pharmacist may not dispense a generic equivalent in
the absence of a request by the purchaser, the Attorney General failed to
elucidate what is meant by "request." It is unlikely that a customer is re-
quired to "initiate" substitution. The law certainly cannot be construed as
prohibiting pharmacists from discussing the provisions of the generic drug
law. It follows that they may also suggest that generic substitution be
performed.
A bill to amend the generic drug law was introduced on June 10, 1975,
which, if passed, will clarify the legislative intent as to the need for a con-
sumer request. House Bill 5325 proposes to amend section 14a(1) to read
as follows:
When a pharmacist receives a prescription for a brand name
drug product, the pharmacist may, or when a purchaser re-
quests a lower cost generically equivalent drug product, the
pharmacist shall dispense a lower cost but not higher cost
generically equivalent drug product if available in the phar-
macy except as provided in subsection (3).83
This language apparently would permit substitution of a generically
equivalent drug in place of the brand-name product prescribed by the
doctor without the patient's consent or even his knowledge in some cases.
The amendment's supporters deny this,8 4 on the ground that proper label-
ing as required by section 14a(l) would notify the customer of the
substitution.85 This assumes, however, that the customer will read the label
and that he will understand that a substitution has occurred. Furthermore,
if the customer does discover the substitution, he has the burden of
demanding, after the prescription has been filled and quite possibly after
he as returned home, that his prescription be filled as written or that he
get his money back. The Michigan Board of Pharmacy proposed amending
the bill to insert the phrase "with the knowledge and consent of the patient"
after the word "may."86 Nevertheless, the bill passed the House without it
on October 28, 1975.87 Hopefully the Senate will add this requirement
82 Understanding H.B. 4145, supra note 58, at 7-8.
83 H.B. 5325, 78th Leg. (1975).
84 Sesti, supra note 70, at 38.
85 MIcH. COMP. LAws ANN. § 338.1114a(1) (Supp. 1975-76) provides in pertinent
part:
If a drug is dispensed which is not the prescribed brand, the prescription
label shall indicate both the name of the brand prescribed and the
name of the brand dispensed and designate each respectively. If the
dispensed drug does not have a brand name, the prescription label
shall indicate the generic name of the drug dispensed ....
86 Sesti, supra note 70, at 38.
87 MiCH. H.R. JOUR. No. 111, at 3271-72 (Oct. 15, 1975); MICH. H.R. JoUR. No.
115, at 3341-44 (Oct. 23, 1975); MICH. H.R. Jou. No. 116, at 3367 (Oct. 28, 1975).
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when it considers House Bill 5325. Substitution should not take place
without regard to the wishes of the customer. Since the main purpose of
this legislation is to save the consumer money, he should have the option
of refusing this benefit if he so desires.
8 8
House Bill 5325 as proposed also would compel a pharmacist to sub-
stitute a lower cost generically equivalent product (if available in the
pharmacy) whenever requested to do so by a customer. This would
be unwise, since it has been demonstrated that not all drugs which are
chemically equivalent (and thus generically equivalent) are therapeutically
equivalent.8 9 In some circumstances, therefore, a pharmacist should not
substitute. One might argue that under these circumstances the prescriber
would indicate that the prescription be dispensed as written. Nevertheless,
the pharmacist should serve as a "check" on the doctor in all events, and
where he feels generic substitution would not be in the patient's best inter-
est, he should not be forced to dispense a substitute.
2. The Savings in Cost Must Be Passed on to the Consumer-Three
provisions of the generic drug law limit the price pharmacists can charge
for an equivalent drug product dispensed in place of a prescribed brand-
name drug.90 Subsection 14a(l) states that, when the customer requests a
"lower cost" generic equivalent, the pharmacist may dispense "a lower
cost but not higher cost" product. 9 Subsection 14a(2) commands that
when substitution occurs, "the pharmacist shall pass on the savings in cost
to the consumer. ' 92 Savings in cost is defined as "the difference between
the wholesale cost to the pharmacist of the 2 drug products. '9 3 Subsection
14a(4) prohibits the pharmacist from dispensing "a drug product with a
total charge that exceeds the total charge of the drug product originally
prescribed, unless agreed to by the purchaser. '94 This last section seems
redundant, and it is not clear why it was included unless it was intended to
clarify the fact that a purchaser can waive the "lower cost" guarantee of
subsection 14a(1). However, if subsection 14a(1) is interpreted as applying
to substitution only when performed in response to a purchaser request,
subsection 14a(4) would prevent a pharmacist from dispensing a more
expensive equivalent product when substituting on his own initiative
(assuming that the pharmacist may select an equivalent drug product with-
88 The Minnesota drug substitution law provides that a
pharmacist who receives a prescription for a brand name legend drug
may, with the written or verbal consent of the purchaser, dispense any
drug having the same generic name ....
MINN. STAT. ANN. § 151.21(2) (Ch. 101 [1975] Minn. Session Law Serv. 295) (em-
phasis added).
The customer should at least be verbally notified of the substitution. See CAL. Bus.
& PROF. CODE § 4047.6 (Ch. 1144 [1975] 7 Deering Advance Leg. Serv. 442); ME.
REV. STAT. ANN. tit. 32, § 2806 (Supp. 1975-76).
89 See part IV A infra.
90MICH. COMp. LAWS ANN. § 338.1114a(l), (2), (4) (Supp. 1975-76).
91 MICH. COMP. LAWS ANN. § 338.1114a(l) (Supp. 1975-76).
92 MICH. COMP. LAWS ANN. § 338.1114a(2) (Supp. 1975-76).
93 Id.
94 MICH. COMp. LAWS ANN. § 338.1114a(4) (Supp. 1975-76).
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out a prior purchaser request). 95 Subsection 14a(2) would apply to both
situations.
These provisions are the very essence of the drug substitution act, since
the purpose of permitting generic substitution is to decrease costs for the
purchasers of prescription drugs. Without a stipulation that the savings
realized through generic, substitution be passed on to the consumer, the
benefits of this legislation might well redound to pharmacists alone.
It is not clear how the state will enforce the requirement that the savings
in acquisition cost be passed on to the consumer. Representative Bert Bren-
nan, in explaining his vote against the generic drug law, stated that a
representative from the Attorney General's office had "publicly admitted
that the section [was] unenforceable." 96 If the law is amended to permit
substitution without a prior purchaser request, consumers will need to be
aware of the existence and relative prices of generically equivalent drug
products in order to protect their right to realize the savings when substi-
tution takes place. The provision of the act which requires pharmacists to
post the prices of the one hundred most frequently prescribed drugs9
should aid the public in this regard. It would also be helpful, however,, to
require any pharmacist substituting a cheaper equivalent in place of the
brand of drug prescribed to verbally notify the customer of the substitution.
This should alert the purchaser to expect to pay a lower charge.
3. The Doctor Must Not Have Exercised His Power to Prevent Substi-
tution-The Michigan drug substitution law allows the prescriber to
prevent drug substitution simply by writing "dispense as written" or
"D.A.W." on a written prescription. 98 The indication must be in the pre-
scriber's own handwriting and cannot be preprinted on the prescription
blank for an obvious reason: such easily taken action would completely
circumvent the law. If the prescription is not in writing, that is, if it is given
verbally, substitution is prevented if the prescriber "expressly indicates the
prescription is to be dispensed as communicated." 99
The "D.A.W." provision can be criticized on the ground that it gives
prescribers power to thwart the law. This contention could be answered,
however, by again pointing out that not all chemically equivalent drugs
produce the same therapeutic effect. 10 0 Since there must be some mech-
95 See part III A 1 supra.
96 MICH. H.R. JOUR. No. 26, at 526 (Feb. 26, 1974).
97 MICH. COMP. LAws ANN. § 338.1114c (Supp. 1975-76).
9s MICH. COMP. LAws ANN. § 338.1114a(3) (Supp. 1975-76).
99 Id. The law further specifies that, if the prescriber has preprinted on his pre-
scription blanks the statement "another brand of a generically equivalent product,
identical in dosage, form, and content of active ingredients, may be dispensed unless
initialed D.A.W.," the prescriber may prevent substitution by writing the initials
D.A.W. in a space, box or square adjacent to such statement. This provision was
added by the Senate. MICH. S. JOUR. No. 74, at 1047-48 (May 29, 1974). Its inclusion
seems unnecessary. Yet the Michigan Attorney General has interpreted it as creating
an exception to the general rule requiring purchaser request prior to generic substitu-
tion. See part III A 1 supra. That this was the legislative intent seems unlikely
whether or not the legislature intended a purchaser request to be a prerequisite for
generic substitution.
100 See part IV A infra.
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anism whereby the prescriber can specify that only one brand of drug be
given to his patient, the requirement that he write out the words "dispense
as written" or the initials "D.A.W." is a reasonable solution. Although a
doctor is not prevented from writing "D.A.W." on every prescription if
he so desires, an affirmative act, indicating a conscious decision on his part,
is required. Unfortunately, in a survey conducted by the Department of
Community Medicine of Wayne State University, 15 percent of the phy-
sicians responding reported that they intend to write "D.A.W." in all
cases. 10' Perhaps as consumers become more aware of this legislation, they
will begin to question such doctors about their rationale for limiting the
patient's options in this way.
The Minnesota drug substitution law also permits substitution of a
generic equivalent only if a prescriber has not written in his own handwrit-
ing "dispense as written" or "D.A.W.' 10 2 However, even when the
prescription is marked "D.A.W.," a pharmacist may substitute
a generically equivalent drug product which is manufac-
tured in the same finished dosage form having the same
active ingredients and strength by the same manufacturer as
the prescribed brand name drug. 10 3
This limits the doctor's prerogative of naming a specific brand, but only in
the situation where one manufacturer has produced a single product which
is then marketed by several drug companies under various names.
B. The Requirement that Drug Prices
Be Displayed
The other major feature of the current legislation is a section compelling
pharmacists "engaged in the business of selling drugs at retail" to post at
each prescription counter the current selling prices of the one hundred
most frequently prescribed drugs. 10 4 This is a significant advance for the
consumer, which will cost the state little in comparison to the benefits it
will provide.10 5 The fact that drug purchasers can now easily compare
prices charged in various pharmacies should foster competition in the retail
sale of drugs.
101 T. GOLDBERG, supra note 16, at 21.
102 MINN. STAT. ANN. § 151.21 (Ch. 101 [1975] Minn. Session Law Serv. 295).
1
03 Id.; MINN. STAT. ANN. § 151.361 (Ch. 101 [1975] Minn. Session Law Serv. 296)
requires that the container of any drug product sold for human use in the state be
labeled with the name and address of the manufacturer of the finished dosage form
of the product.
lO4 MICH. COMP. LAws ANN. §§ 338.1101(ff), 338.1114c (Supp. 1975-76). The
statute applies to hospital pharmacies serving outpatients as well as to retail
pharmacies.
105 The State Board of Pharmacy was given the responsibility to publish and
distribute posters showing the one hundred most frequently prescribed drugs. The
cost of this was estimated to be approximately $2,600, based upon distribution of the
list on a quarterly basis to the 2500 pharmacies in the state. Analysis Section, Mich.
H.R., Analysis-H.B. 4145 (Nov. 6, 1974).
[VOL. 9:394
Michigan's Generic Drug Law
IV. PROBLEMS NOT ADDRESSED BY THE
CURRENT GENERIC DRUG ACT
A. Therapeutic Equivalency
Serious questions have been raised as to whether drug products of the
same chemical structure, drugs which are generically equivalent, are
therapeutically equivalent. 10 6 Drugs are considered therapeutically equiva-
lent if, when administered to the same individuals in the same dosage regi-
men, they provide essentially the same efficacy and/or toxicity.1'0 7
In April 1974 the Office of Technology Assessment convened an expert
Drug Bioequivalence Study Panel in order
to examine the relationships between the chemical and
therapeutic equivalence of drug products and to assess the
capability of current technology . . . to determine whether
drug products with the same physical and chemical compo-
sition produce comparable therapeutic effects. 108
The Drug Bioequivalence Study Panel produced a report which was made
public just one month after the Michigan generic drug bill was signed by
the Governor. The study panel concluded that not all chemically equiva-
lent drugs are therapeutically interchangeable. 10 9 Furthermore, the problem
of therapeutic inequivalence was viewed as an important one, in spite of
the fact that the number of instances of demonstrable inequivalence is
small. 110 Nevertheless, the panel indicated that the goal of interchange-
ability was achievable within most classes of drug products and set out
recommendations for meeting this goal."'
Kentucky has dealt squarely with the issue of therapeutic equivalency.
Its drug substitution law creates a Drug Formulary Council which is re-
sponsible for preparing a formulary of generic drugs which it determines
to be therapeutically equivalent to specified brand-name drugs. 112 Phar-
106 E.g., DRUG BIOEQUIVALENCE STUDY PANEL, OFFICE OF TECHNOLOGY ASSESS-
MENT, DRUG BIOEQUIVALENCE (1974), printed in Brand Names and Generic Drugs,
Hearing on Examination of the Office of Technology Assessment Report of the
Drug Bioequivalence Study Panel Before the Subcomm. on Health of the Senate
Comm. on Labor and Public Welfare, 93d Cong., 2d Sess. 3-80 (1974) [herein-
after cited as DRUG BIOEQUIVALENCE]; NATIONAL ACADEMY OF SCIENCES, DRUG
EFFICACY STUDY 241 (1969); Academy of Pharmaceutical Sciences, Drug Product
Quality, NS10 J. Am. PHARM. Ass'N 107 (1970); Schneller, Hazard of Therapeutic
Inequivalency of Drug Products, NS9 J. AM. PHARM. ASS'N 455 (1969); Sokoloski,
Rational Selection of One of Several Generic Products, 13 MICH. PHARM. 9 (Jan.
1975). But see TASK FORCE ON PRESCRIPTION DRUGS, DEPARTMENT OF HEALTH,
EDUCATION, AND WELFARE, FINAL REPORT 31 (1969). Additional sources are cited
in Willig, supra note 9, at 8-14 and Note, supra note 8, at 890-96.
107 DRUG BIOEQUIVALENCE, supra note 106, at 78.
108 Id. at 5.
109 Id. at 13.
110 Id. at 14.
111 Id. at 58-60. An explanation of the factors leading to therapeutic inequivalence
of chemically equivalent drugs is beyond the scope of this note. The reader is re-
ferred to DRUG BIOEQUIVALENCE and other sources cited in note 106 supra.
112 KY. REV. STAT. ANN. §§ 217.818-.819 (Supp. 1974).
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macists may interchange only drugs appearing on this list.113 In practice,
however, this solution has proved to be cumbersome. As of December 1,
1975, the Council had only agreed to place eighteen drugs on the
formulary. 114 It is questionable whether the value of this list will justify the
cost of its production. 115
California may have more success with its "negative formulary." 116 This
formulary, to be established by the Director of Health, is to include
generic drug types and drug products which the Director of
Health determines demonstrate clinically significant bio-
logical or therapeutic inequivalence and which, if substi-
tuted ... would pose a threat to the health and safety of pa-
tients receiving prescription medication.
117
The Director of Health is to rely upon testing and research as well as
formularies drawn up by other states, the Department of Health, Education,
and Welfare and any other reliable sources.1 18 A pharmacist is prohibited
from performing generic substitution for drugs on this list.119
The California plan is an excellent compromise between placing no re-
strictions at all on generic substitution and confining substitution to drugs
listed on a "positive" formulary. This approach prevents the drug con-
sumer from buying a drug which, while chemically equivalent to that
prescribed by his doctor, has been shown to produce a different therapeutic
effect. Furthermore, this benefit is achieved without expending vast sums
of money or requiring the agreement of a body of experts. Library research
will quickly turn up documented studies of demonstrated bioinequiva-
113 KY. REV. STAT. ANN. § 217.822 (Supp. 1974).
114 Letter from N. Earl Becknell to author, Dec. 1, 1975 (on file with the Uni-
versity of Michigan Journal of Law Reform). However, eleven more drug families
were scheduled for addition, effective mid-December. Id. (The law creating the
Council was enacted in 1972.)
115 The sum of $100,000 was appropriated to the Council for its first two years of
operation. Id.
Massachusetts law also provides for establishment of a formulary. MASS. GEN.
LAWS ANN. ch. 17, § 13 (1973). However, rather than permitting a pharmacist to
substitute from the list, the law requires that the doctor prescribing a listed drug
must indicate the generic name on the prescription. MAss. GEN. LAWS ANN. ch. 112,
§ 12D (1975).
Maryland limits generic substitution to drugs listed in a state formulary or ap-
proved for listing by the Department of Health, Education, and Welfare according
to regulations entitled Maximum Allowable Cost for Drugs, 45 C.F.R. Part 19.
MD. ANN. CODE art. 43, § 273A (Cum. Supp. 1975). 45 C.F.R. § 19.5 (1975)
establishes procedures for identifying "multiple-source drugs for which significant
amounts of Federal funds are or may be expended . . .and for which there are or
may be significantly different prices." Reimbursement (under federal programs)
for selected drugs would be limited to the lowest price "at which the drug is widely
and consistently available from any formulator or labeler." 45 C.F.R. § 19.3 (1975).
See notes 127-29 and accompanying text infra.
116 CAL. Bus. & PROF. CODE § 4047.7 (Ch. 1144 [1975] 7 Deering Advance Leg.
Service 442). Arkansas has a similar provision. ARK. STAT. ANN. §§ 72-1047 to -1049
(Supp. 1975).
117 CAL. Bus. & PROF. CODE § 4047.7 (Ch. 1144 [1975] 7 Deering Advance Leg.
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lence. 120 A positive formulary is more difficult to compile because far less
consensus exists in recognizing drugs which can be safely interchanged
than in identifying products which should not be substituted.
The Drug Bioequivalence Study Panel recommended that the federal
government compile a list of interchangeable drugs.121 A project of this
magnitude would be an ambitious proposition for a state to undertake and
its benefits would probably be outweighed by its cost. If the federal govern-
ment were to undertake such a study, on the other hand, the effort would
be considerably more worthwhile. Once a list of equivalent drugs was pro-
duced, states having generic drug laws could adopt the resulting list as a
formulary from which the pharmacist could select substitutions.
12 2
B. Third-Party Payment Plans
In Michigan over three million citizens are covered by pre-payment bene-
fits for pharmacy care. 1' 3 Yet the Michigan generic drug law provides no
incentive for a consumer who has insurance to request substitution. In fact,
the law now provides that the savings in cost need not be passed on to a
third-party payment source when generic substitution occurs. 124 This ex-
ception for purchases covered by third-party payment contracts was prob-
ably made because these contracts usually provide that the pharmacist will
only be reimbursed the wholesale price of the drug dispensed plus a flat
service fee.12 5 Nevertheless, the bill presently before the Michigan Senate
would amend the law to require that the savings in cost be passed on to a
third-party payment source if the prescription is covered by a third-party
payment contract.12 6 This reform may not save much money for insurance
companies, however, because purchasers covered by insurance will not
necessarily desire a cheaper generic drug. On the contrary, they may well
demand "the best money can buy" in spite of the fact that the increased
costs of health care are reflected in the premiums charged for health
insurance.
120 Differences in bioavailability (bioinequivalence) among some drug products
may not be of concern in all cases. This is because many drugs have a wide range
between the concentration of active ingredient in the body fluids which is needed
to produce a desired therapeutic effect and that which produces unwanted toxic ef-
fects. On the other hand, for drugs with a narrow margin of safety, a difference in
bioavailability can be crucial. DRUG BIOEQUIVILANCE, supra note 106, at 22-23. The
Drug Bioequivalence Study Panel proposed guidelines for determining the drugs
for which bioequivalence would be critical and therefore for which bioavailability
studies are essential. DRUG BIOEQUIVALENCE, supra note 106, at 23-24. Presumably,
these drugs would be placed on a negative formulary until such time as their bio-
equivalence was affirmatively demonstrated.
121 DRUG BIOEQUIVALENCE, supra note 106, at 57-60.
122 Present uncertainty about therapeutic equivalency may make pharmacists fear
increased liability and therefore hesitate to substitute generically. For a discussion
of liability issues, see Note, supra note 8, at 897-904.
123 Kenneth Cook Testifies on H.B. 4145, 12 MICH. PHARM. 8 (Sept. 1974).
1 24 MICH. COMP. LAws ANN. § 338.1114a(2) (Supp. 1975-76).
125 Understanding H.B. 4145, supra note 58, at 8.
126 H.B. 5325, 78th Leg. (1975).
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In some situations health insurers have attempted to decrease expendi-
tures by reimbursing the insured only for the cost of certain approved ex-
penses, for example, a semi-private hospital room. The Department of
Health, Education, and Welfare is attempting to apply similar restrictions
to the reimbursement of drug providers under federally funded programs
such as Medicare. 127 Drugs to which the "maximum allowable cost policy"
will apply will be listed in the Federal Register.1 28 Reimbursement for these
drugs will be limited to the lowest cost at which each drug is widely avail-
able plus a reasonable dispensing fee.'
29
If a list of interchangeable drugs were generated by the federal govern-
ment as proposed by the Drug Bioequivalence Study Panel and were
adopted by the state as a formulary, private insurers could reasonably limit
reimbursement for any given multi-source drug to the amount for which
it could be obtained from the least expensive source approved for inclusion
on the formulary.
V. CONCLUSION
The Michigan generic drug law in its present form is an acceptable solu-
tion to the problem of delivering quality pharmaceutical care at competitive
prices. The most effective way to achieve this goal would be to empower
a panel of experts to compile a list of therapeutically equivalent drugs and
permit substitutions from that list. However, due to the expense of such an
undertaking and the fact that most drugs do not have known equivalency
problems associated with them, this method was not adopted. 130 Instead,
the Michigan drug substitution law requires the consent of three persons
before generic substitution can take place: the doctor must not prohibit
substitution, the patient must request the exchange, and the pharmacist
must be willing to select a brand other than the brand prescribed. This
approach gives pharmacists broader latitude in the exercise of professional
judgment and helps drug purchasers save money on prescriptions. It is
unclear, however, whether a purchaser must initiate generic substitution
or merely agree to it. The law should therefore be amended to remove the
ambiguous "purchaser request" language, but the right of a consumer to be
consulted about the selection of the drug product he will purchase should
be retained.
Any amendment to the generic drug law must accommodate the policies
of decreasing the cost of drugs, expanding the professional role played by
pharmacists in drug product selection, and increasing the right of the con-
sumer to choose the product he will purchase. The bill presently before the
Michigan Legislature gives disproportionate emphasis to the factor of re-
ducing drug cost. It would compel the pharmacist to substitute upon con-
127 45 C.F.R. §§ 19.1-19.6 (1975).
12845 C.F.R. § 19.5 (1975).
12945 C.F.R. § 19.3 (1975).
130 The major benefits of a formulary can be achieved with relatively little expense
by compiling a negative formulary, however. See notes 116-20 and accompanying
text supra.
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sumer demand even where substitution in his judgment violated good
pharmaceutical practice. It would also permit substitution to occur against
the wishes of the consumer. Such a policy choice would be less objection-
able if it were combined with either a positive or negative formulary.
Until such a safeguard exists, however, consent of all three parties con-
cerned in a patient's drug therapy should remain a prerequisite for generic
substitution.
-Phyllis Greenwood Rozof
